Table 2.
MTX-induced IVLBCL in the Literature.
| Sex, age | Symptoms | CNS invasion | Diagnosis | EBV infection | Anti-Rheumatoid drugs | Interval from MTX to LPD | Therapy | Response | References |
|---|---|---|---|---|---|---|---|---|---|
| F, 50Y | Fever, eruption | Y | Skin | N | MTX+Etanercept | 3 Y | R-CHOP+IT | CR | 8 |
| F, 75Y | Fever | Y | Skin | N | MTX | 2M | R-HyperCVAD/MA | CR | 9 |
| M,77Y | Fever | N | Skin | N | MTX, Iguratimod | 10Y | R-THP-COP | CR | Present case |
R-CHOP: rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone, R-THP-COP: rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone, CVAD/MA: cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate and cytarabine, CR: complete remission